Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy

Cancer

Volumn 118, Issue 17, 2012, Pages 4156-4165

  Campbell, Belinda A ^a,b,c   Connors, Joseph M ^b   Gascoyne, Randy D ^b,c   Morris, W James ^c   Pickles, Tom ^c   Sehn, Laurie H ^b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

diffuse large B cell lymphoma; lymphatic irradiation; lymphoma; radiotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INVOLVED FIELD RADIOTHERAPY; INVOLVED NODE RADIOTHERAPY; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; SYSTEMIC THERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC IRRADIATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84865347010     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26687     Document Type: Article

References (34)

1. Swerdlow S, Campo E, Harris N, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
2. Ng AK,. Diffuse large B-cell lymphoma. Semin Radiat Oncol. 2007; 17: 169-175.
3. Persky DO, Miller TP,. Localized large cell lymphoma: is there any need for radiation therapy? Curr Opin Oncol. 2009; 21: 401-406.
4. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998; 339: 21-26.
5. Shenkier TN, Voss N, Fairey R, et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol. 2002; 20: 197-204.
6. Bonnet C, Fillet G, Mounier N, et al. Groupe d'Etude des Lymphomes de l'Adulte. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2007; 25: 787-792.
7. Phan J, Mazloom A, Jeffrey Medeiros L, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol. 2010; 28: 4170-4176.
8. Persky DO, Unger JM, Spier CM, et al. Southwest Oncology Group. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol. 2008; 26: 2258-2263.
9. Pfreundschuh M, Trümper L, Osterborg A, et al. MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7: 379-391.
10. Tilly H, Dreyling M,; ESMO Guidelines Working Group. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009; 20 (suppl 4): 110-112.
11. Zelenetz AD, Advani RH, Byrd JC, et al. National Comprehensive Cancer Network. Non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 2008; 6: 356-421.
12. Wirth A,. The rationale and role of radiation therapy in the treatment of patients with diffuse large B-cell lymphoma in the Rituximab era. Leuk Lymphoma. 2007; 48: 2121-2136.
13. Illidge T, Tolan S,. Current treatment approaches for diffuse large B-cell lymphoma. Leuk Lymphoma. 2008; 49: 663-676.
14. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006; 24: 3121-3127.
15. Friedberg JW, Fisher RI,. Diffuse large B-cell lymphoma. Hematol Oncol Clin North Am. 2008; 22: 941-952.
16. Reyes F, Lepage E, Ganem G, et al. Groupe d'Etude des Lymphomes de l'Adulte. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005; 352: 1197-1205.
17. André M, Mounier N, Leleu X, et al. Groupe d'Etude des Lymphomes de l'Adulte. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood. 2004; 103: 1222-1228.
18. Kelsey CR, Beaven AW, Diehl LF, Prosnitz LR,. Radiation therapy in the management of diffuse large B-cell lymphoma: still relevant? Oncology (Williston Park). 2010; 24: 1204-1212.
19. Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol. 2004; 22: 3032-3038.
20. Campbell BA, Voss N, Pickles T, et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size. J Clin Oncol. 2008; 26: 5170-5174.
21. Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol. 2006; 79: 270-277.
22. Campbell B, Wirth A, Cunninghame J, et al. Involved node radiotherapy significantly reduces lung, breast and thyroid dose in patients with limited stage Hodgkin lymphoma. Haematologica. 2010; 95 (suppl 4): S13.
23. Campbell BA, Voss N, Woods R, et al. Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer. 2010; 116: 3797-3806.
24. Eich HT, Müller RP, Engenhart-Cabillic R, et al. German Hodgkin Study Group. Involved-node radiotherapy in early-stage Hodgkin's lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol. 2008; 184: 406-410.
25. Yahalom J,. Radiation therapy after R-CHOP for diffuse large B-cell lymphoma: the gain remains. J Clin Oncol. 2010; 28: 4105-4107.
26. Miller TP, Leblanc M, Spier C, et al. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial (Abstract). Blood. 2001; 98 (suppl): S742-S743.
27. Ballonoff A, Rusthoven KE, Schwer A, et al. Outcomes and effect of radiotherapy in patients with stage I or II diffuse large B-cell lymphoma: a surveillance, epidemiology, and end results analysis. Int J Radiat Oncol Biol Phys. 2008; 72: 1465-1471.
28. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 235-242.
29. Weber DC, Peguret N, Dipasquale G, Cozzi L,. Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study. Int J Radiat Oncol Biol Phys. 2009; 75: 1578-1586.
30. Campbell BA, Hornby C, Cunninghame J, et al. Minimising critical organ irradiation in limited stage Hodgkin lymphoma; a dosimetric study of the benefit of involved node radiotherapy. Ann Oncol. 2011 (Epub ahead of print).
31. Isobe K, Kawakami H, Tamaru J, et al. Consolidation radiotherapy following brief chemotherapy for localized diffuse large B-cell lymphoma: a prospective study. Leuk Lymphoma. 2003; 44: 1535-1539.
32. Yu JI, Nam H, Ahn YC, Kim WS, Park K, Kim SJ,. Involved-lesion radiation therapy after chemotherapy in limited-stage head-and-neck diffuse large B cell lymphoma. Int J Radiat Oncol Biol Phys. 2010; 78: 507-512.
33. Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC,. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica. 2006; 91: 522-529.
34. Dunleavy K, Mikhaeel G, Sehn LH, Hicks RJ, Wilson WH,. The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma. Leuk Lymphoma. 2010; 51 (suppl 1): 28-33.